Last updated: April 25, 2026
What is colchicine’s supply chain structure?
Colchicine is produced from Colchicum (autumn crocus) plants or via synthetic/semisynthetic routes for bulk active ingredient (API) and is then distributed through a tiered model:
- API manufacturers that produce colchicine (bulk API)
- Finished-dose manufacturers that formulate and package colchicine products
- Wholesalers and importers that source colchicine API and finished products across jurisdictions
A complete “supplier list” depends on whether the buyer is seeking API (for manufacturing) or commercial finished dosage forms (for direct procurement). The sourcing universe also varies by regulatory status, because colchicine products are marketed under different brand and label strengths and may reference different manufacturers.
Which global companies manufacture colchicine (API) and/or sell it as an API?
The market includes specialty generics and API players that sell colchicine API and contract manufacturing services for colchicine-containing products. The supplier set typically includes companies with:
- plant-extraction or controlled-source procurement for colchicine-rich botanicals, and/or
- established small-molecule API synthesis and purification capability for colchicine.
Which finished-dose manufacturers market colchicine products (examples by region)?
Colchicine is widely marketed in tablet form for indications such as gout and pericarditis. Supplier names for finished products differ by country because of local marketing authorizations and packaging.
- Generic and branded product manufacturers list their product authorization holders and local marketing authorizations on country registries.
- Wholesalers then distribute those finished products, not the API.
Procurement reality for colchicine
For procurement, buyers typically request one of two documentation sets:
- API procurement package: DMF/CEP/CoA, impurity profile, specification sheet, route of synthesis statement, and regulatory status (where applicable).
- Finished-dose procurement package: GMP certificate, batch release documentation, package configuration, and regional product authorization details.
Key supplier categories to screen for colchicine procurement
When mapping suppliers for colchicine, screen for these controllables that impact compliance and continuity:
| Supplier category |
What it controls |
Why it matters for colchicine |
| API producer |
API specs, impurity controls, GMP batch consistency |
Colchicine purity and impurities drive safety and regulatory acceptance |
| Finished-dose manufacturer |
formulation control and packaging |
product availability depends on local regulatory and manufacturing capacity |
| Trading/wholesaler |
logistics, allocation, import compliance |
supply risk often sits in distribution when API supply tightens |
Regulatory and documentation signals used to qualify colchicine suppliers
Procurement teams typically verify:
- Regulatory listing in target jurisdiction
- GMP status for API or finished product
- Quality documentation: CoA per batch and validated specs
- Change control: supplier change notices for synthesis route or purification steps
Key Takeaways
- Colchicine supply is delivered through API producers, finished-dose manufacturers, and wholesalers/importers.
- Supplier qualification hinges on API specifications, impurity profiles, GMP status, and batch CoA traceability, not only availability.
- A practical supplier map must be built by procurement type: API vs finished dosage forms and by target jurisdiction, because labeled products and authorization holders vary by country.
FAQs
-
Is colchicine supplied mainly as API or as finished tablets?
Both exist, but manufacturing buyers generally source colchicine API, while end-market procurement often buys finished tablets under local authorization.
-
What documents matter most when qualifying colchicine suppliers?
CoA per batch, specification sheet, and GMP/regulatory status for the relevant jurisdiction and product form (API or finished dose).
-
Do the same companies supply both API and finished doses?
Some companies span multiple tiers, but procurement usually distinguishes API producers from finished-dose manufacturers.
-
What supply risk drives colchicine allocation issues?
Botanical/controlled sourcing and manufacturing batch continuity for API, plus regulatory packaging/manufacturing capacity for finished doses.
-
How do procurement teams map suppliers efficiently?
They start with jurisdiction-specific product authorizations for finished doses and API regulatory dossiers (where used) plus GMP verification for API.
Cited Sources
[1] FDA. “Drug Shortages” (colchicine and related listings when applicable). U.S. Food and Drug Administration. https://www.fda.gov/drugs/drug-shortages
[2] European Medicines Agency (EMA). Public assessment documents and product information for colchicine-containing medicines. https://www.ema.europa.eu
[3] U.S. National Library of Medicine. PubChem Compound Summary: Colchicine. https://pubchem.ncbi.nlm.nih.gov
